Mr. John Slattery
John Slattery is the Director of Research and Innovation for Aces Health. Prior to his time at Aces, John worked in Academia at UPenn and Arkansas Children’s Hospital/UAMS. He has conducted systems level Neuroscience (fMRI and DTI, perfusion imaging) investigating neural correlates of attention networks after a traumatic brain injury or stroke. Mr. Slattery has a few publications on this work. After his stint at Penn, John transitioned to clinical research on neurodevelopmental disorders (particularly Autism Spectrum Disorders (ASD). During this time, he
completed the first DBPC trial in ASD in which a medical intervention improved core and associated ASD symptoms and through biomarkers could predict which children would respond based on a biomarker in their body. It was billed the first positive precision medicine initiative in psychiatry. John has authored or co-authored over 35 publications based on our ASD work related to oxidative stress, mitochondrial dysfunction, enteric ecosystem disruption, metabolism, and immune dysfunction and 1 book chapter on the usage of N-acetylcsytine in Neuropsychiatry. He sits on a few scientific advisory boards and is considered an expert in systems level biology in relation to CNS disorders.
What motivated John to join Aces Health was the need for a digital health ecosystem to take disparate data sources and have all data that can be collected from a patient (genetic/epigenetic, exposome, microbiome, proteomics, metabolomics, lifestyle, ePRO, eCOA, EHRs, etc) all within a unified and centralized platform.
John’s speciality is anything clinical trial design particularly in leveraging Health initiatives into CNS related disorders.